Study guide
2.6 Clinical Toxicology, Therapeutic Drug Monitoring (TDM), and Pharmacokinetics
AMT Medical Laboratory Scientist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: General Laboratory Operations, Safety & Quality
1.1 Laboratory Safety, OSHA Standards, Hazard Communication, and Biohazard Control 1.2 Quality Systems, Quality Control, and Westgard Rules Interpretation 1.3 Specimen Collection, Handling, Order of Draw, and Phlebotomy Complications 1.4 Laboratory Instrumentation, Photometry, Spectrophotometry, and Centrifugation 1.5 Laboratory Mathematics, Dilutions, Solution Preparation, and Standard Curves 1.6 Regulatory Compliance, CLIA '88 Regulations, Accreditation, and Laboratory Ethics
2 Chapter 2: Clinical Chemistry & Metabolic Testing
2.1 Carbohydrate Metabolism, Glucose Regulation, Diabetes Mellitus, and HbA1c 2.2 Proteins, Non-Protein Nitrogenous Compounds (BUN, Creatinine, Uric Acid), and Renal Function 2.3 Enzymology and Organ Systems 2.4 Electrolytes, Acid-Base Balance, Anion Gap, and Blood Gas Analysis 2.5 Clinical Endocrinology, Thyroid, Adrenal, and Reproductive Hormones 2.6 Clinical Toxicology, Therapeutic Drug Monitoring (TDM), and Pharmacokinetics 2.7 Lipids, Lipoproteins, and the Friedewald LDL Calculation
3 Chapter 3: Hematology & Leukocyte Disorders
3.1 RBC Indices and Anemia 3.2 WBC Differential and Benign Disorders 3.3 Hematologic Malignancies 3.4 Hemoglobin Structure, Hemoglobinopathies (Sickle Cell, Thalassemia), and Variants 3.5 Hematology Automation, Flow Cytometry, and Cell Counting Technology
4 Chapter 4: Coagulation & Hemostasis
4.1 Primary and Secondary Hemostasis, Platelet Function, and Vascular Integrity 4.2 Coagulation Cascade Disorders 4.3 Coagulation Testing and Anticoagulants
5 Chapter 5: Immunology & Serology
5.1 Immune Mechanisms, Hypersensitivity Reactions, and Autoimmune Disease Testing 5.2 Serological Testing Principles and Infectious Serology
6 Chapter 6: Immunohematology & Blood Grouping
6.1 ABO and Rh Blood Group Systems, Antigens, Subgroups, and Weak D Variant 6.2 Red Cell Antibody Screening, Identification Panels, and Dosage Effects 6.3 Direct and Indirect Antiglobulin Testing (DAT/IAT) and Troubleshooting 6.4 Compatibility Testing, Crossmatching, and Hemolytic Disease of the Fetus and Newborn
7 Chapter 7: Blood Banking & Transfusion Medicine
7.1 Blood Donor Selection, Screening, Collection, and Component Storage 7.2 Transfusion Practice, Indications for Blood Components, and Administration 7.3 Transfusion Reactions: Investigation Protocol and Reaction Classification
8 Chapter 8: Clinical Microbiology
8.1 Specimen Processing, Gram Stain, and Aerobic Gram-Positive Cocci 8.2 Gram-Negative Bacilli: Enterobacteriaceae, Non-Fermenters, and Fastidious Organisms 8.3 Anaerobic Bacteria, Mycobacteria, Acid-Fast Stains, and Molecular Diagnostic Methods 8.4 Clinical Mycology and Medical Parasitology 8.5 Antimicrobial Susceptibility Testing, Resistance, and Virology
9 Chapter 9: Urinalysis & Body Fluids
9.1 Physical and Chemical Examination of Urine and Reagent Strip Principles 9.2 Microscopic Urinalysis: Cells, Casts, Crystals, and Renal Pathology 9.3 Analysis of Cerebrospinal Fluid (CSF), Serous Fluids, and Synovial Fluid
2.6 Clinical Toxicology, Therapeutic Drug Monitoring (TDM), and Pharmacokinetics
Key Takeaways Explain This Topic AI
Peak TDM samples assess toxicity and are drawn typically 1-2 hours post-dose, whereas trough samples assess sub-therapeutic levels and are drawn immediately before the next dose.
Acetaminophen toxicity is evaluated using the Rumack-Matthew nomogram; the specific antidote to prevent hepatotoxicity is N-acetylcysteine.
Digoxin is a cardioactive drug with a narrow therapeutic index (0.8-2.0 ng/mL); toxicity is severely exacerbated by hypokalemia.
Aminoglycosides (e.g., gentamicin, tobramycin, vancomycin) require careful TDM due to their potential to cause irreversible nephrotoxicity and ototoxicity.
Fetal wellness chemistry includes fetal fibronectin, AFP, L/S ratio for lung maturity, and amniotic fluid ΔA450 for fetal hemolysis risk.
Last updated: July 2026
Clinical Toxicology, Therapeutic Drug Monitoring (TDM), and Pharmacokinetics
The medical laboratory plays a crucial role in pharmacology through Therapeutic Drug Monitoring (TDM) and clinical toxicology. TDM ensures that drug levels remain within a narrow therapeutic window, preventing toxicity while maintaining efficacy. Toxicology identifies illicit or toxic substances to guide emergency interventions.
1. Pharmacokinetics and TDM Basics
Pharmacokinetics studies what the body does to a drug, governed by four phases: A bsorption, D istribution, M etabolism, and E xcretion (ADME).
Steady State : Achieved when the amount of drug administered exactly balances the amount of drug eliminated. It typically takes 5 to 7 half-lives to reach steady state. TDM is usually only valid after steady state is reached.
First-Pass Effect : Oral drugs pass through the liver via the portal vein before reaching systemic circulation, which can heavily metabolize the drug before it exerts its intended effect.
Timing of Specimen Collection
For drugs with a narrow therapeutic index, blood collection timing is heavily standardized:
Trough Levels : The lowest concentration, collected immediately before the next scheduled dose. Trough monitoring ensures the drug level doesn't fall below the Minimum Effective Concentration (MEC).
Peak Levels : The highest concentration, collected after absorption and distribution are complete (typically 1 to 2 hours after an oral dose, or 30-60 mins after an IV dose). Peak monitoring ensures levels do not exceed the Minimum Toxic Concentration (MTC).
- 2. Common Drugs Monitored (TDM)
- Cardioactive Drugs
Digoxin : Used to treat congestive heart failure and arrhythmias.
Therapeutic Range : 0.8–2.0 ng/mL.
Clinical Note : Digoxin toxicity is severely exacerbated by hypokalemia (low potassium). TDM for digoxin must always be coupled with basic metabolic panels to evaluate electrolytes.
Antibiotics
Aminoglycosides (Gentamicin, Tobramycin, Amikacin) : Used for severe gram-negative bacterial infections.
Toxicity : Severe side effects include nephrotoxicity (kidney damage) and ototoxicity (irreversible hearing loss). Both peak and trough levels are strictly monitored.
Vancomycin : Used for severe gram-positive infections (e.g., MRSA). Monitored primarily via trough levels to prevent nephrotoxicity and avoid "Red Man Syndrome" associated with rapid infusion.
Chloramphenicol : Historically used antibiotic known for causing "Gray Baby Syndrome" in neonates due to their inability to metabolize the drug.
Antiepileptics (Anticonvulsants)
Phenytoin (Dilantin) , Valproic Acid , Carbamazepine , and Phenobarbital are commonly monitored to prevent seizures while avoiding severe neurological depression and hepatotoxicity.
Psychoactive Drugs
Lithium : The standard treatment for bipolar disorder (manic-depressive illness).
Therapeutic Range : 0.6–1.2 mmol/L.
Measurement : Uniquely, it does not bind proteins. Traditionally measured using Ion-Selective Electrodes (ISE) or atomic absorption spectrophotometry.
Bronchodilators
Theophylline : Treats severe asthma and COPD.
Clinical Note : Has a very narrow therapeutic index. In premature neonates being treated for apnea, theophylline rapidly metabolizes into caffeine, which acts as the active stimulant.
Immunosuppressants
Cyclosporine, Tacrolimus, Sirolimus : Used to prevent organ transplant rejection.
Specimen Choice : These drugs sequester inside red blood cells. Therefore, they must be monitored using whole blood (typically drawn in an EDTA tube) rather than serum or plasma. Analyzed primarily via LC-MS/MS or specific immunoassays.
3. Clinical Toxicology
Toxicology deals with the detection of poisons, toxins, heavy metals, and drugs of abuse.
Acetaminophen (Tylenol) Overdose
Acetaminophen is a common over-the-counter analgesic. In overdose, normal hepatic conjugation pathways are saturated, leading to the buildup of a highly toxic intermediate metabolite known as NAPQI .
Toxicity : Causes severe, potentially fatal hepatotoxicity (hepatic necrosis).
Diagnosis : Serial blood levels are plotted on the Rumack-Matthew nomogram (evaluating concentration versus hours post-ingestion) to determine the statistical risk of liver damage.
Antidote : N-acetylcysteine (Mucomyst) , which replenishes hepatic glutathione stores allowing for the safe detoxification of NAPQI.
Salicylates (Aspirin) Overdose
Toxicity : Aspirin stimulates the respiratory center causing an initial respiratory alkalosis (due to hyperventilation), which is followed rapidly by a severe high-anion-gap metabolic acidosis .
Measurement : Trinder reaction (a colorimetric reaction utilizing ferric chloride).
Alcohols
Ethanol : The most common drug of abuse. Measured via enzymatic assays (Alcohol Dehydrogenase) or gas chromatography.
Pre-analytical Exam Trap : Do not prep the venipuncture site with an alcohol swab, as it may falsely elevate the legal result. Use non-alcohol solutions like iodine or soap and water.
Methanol : Found in antifreeze and window washer fluid. It metabolizes to formaldehyde and formic acid, causing severe metabolic acidosis, optic nerve damage, and blindness .
Heavy Metals and Gases
Lead (Pb) : Causes severe neurological deficits in children. In hematology, it presents with basophilic stippling in red blood cells. Accurately measured by Inductively Coupled Plasma Mass Spectrometry (ICP-MS).
Carbon Monoxide (CO) : An odorless gas that binds to hemoglobin with 200x greater affinity than oxygen, forming carboxyhemoglobin . Causes cherry-red skin color and fatal hypoxia. Measured rapidly using a co-oximeter.
Drugs of Abuse Screening
Urine is the specimen of choice for drugs of abuse screening due to higher drug concentrations and longer detection windows compared to blood.
Screening : Typically performed using rapid, highly sensitive, but less specific immunoassays.
Confirmation : All positive screens must be legally confirmed using a highly specific methodology, most often Gas Chromatography-Mass Spectrometry (GC-MS) , which is considered the gold standard.
Adulteration Checks : Urine samples are tested for specific gravity, creatinine, pH, and temperature (which should be 32.5–37.7°C within 4 mins of collection) to ensure the patient has not diluted, substituted, or chemically adulterated the sample.
Tumor Markers (AMT Chemistry — Other Procedures)
Tumor markers are substances produced by tumors or by the host in response to tumor growth. They support monitoring and sometimes screening, but they are rarely diagnostic alone.
- Marker Primary Clinical Association
- PSA (prostate-specific antigen) Prostate cancer monitoring / screening adjunct
- CEA (carcinoembryonic antigen) Colorectal and other adenocarcinomas (monitoring)
- CA 125 Ovarian epithelial carcinoma monitoring
- CA 19-9 Pancreatic / biliary tract adenocarcinoma
- CA 27-29 Breast cancer monitoring
- β-hCG Germ-cell tumors and pregnancy (context matters)
- HER2 Breast cancer: IHC first; equivocal results reflex to FISH for amplification
HER2 cascade (high-yield): Immunohistochemistry (IHC) scores 0/1+ = negative, 3+ = positive, 2+ = equivocal → confirm with FISH (or equivalent ISH). Overexpressed or amplified HER2 guides targeted therapy eligibility.
Fetal Wellness Chemistry Tests
The AMT outline also lists fetal-wellness assays:
Fetal fibronectin (fFN): Cervicovaginal swab used as a negative predictor of preterm delivery in symptomatic patients within a defined gestational window.
AFP (alpha-fetoprotein): Maternal serum AFP is part of prenatal aneuploidy/NTD screening; amniotic fluid AFP rises with open neural-tube defects.
L/S ratio (lecithin/sphingomyelin): Amniotic fluid phospholipid ratio assessing fetal lung maturity; historically L/S ≥2.0 suggested maturity (method-dependent cutoffs).
ΔA450 (delta OD 450): Spectrophotometric measure of amniotic-fluid bilirubin in alloimmunized pregnancies (Liley/Queenan zones) to estimate fetal hemolytic risk.